Europe Oncology Genomics Tracker Captures Oncologist Perspectives Across Major European Markets - Data Report by DeciBio Consulting LLC - Silicon Canals

"A new survey-based Genomics Tracker focused on the EU-5 (France, Germany, Italy, Spain, and the United Kingdom) by DeciBio Consulting LLC provides updated insight into how genomics technologies are being evaluated, adopted, and used across Europe's solid tumor oncology markets. The study is based on responses from 100+ medical oncologists and offers a cross-market view of current priorities, barriers, and areas of momentum."

"The Europe Oncology Genomics Tracker characterizes the current clinical use of genomic testing across a patient's treatment journey (e.g., genomic profiling, MRD / recurrence monitoring, treatment response monitoring) and tracks how use changes over time. Oncology respondents were asked about their use of genomic testing in routine clinical practice within the past three months, as well as their familiarity with various vendors in the ecosystem."

"Adoption of precision medicine is growing steadily across Europe, though each market presents unique drivers and moderators. The country-specific healthcare frameworks and infrastructure in Europe require different strategies for precision oncology than what we see in the U.S. Having visibility into genomics testing practices in these regions is critical for any precision oncology stakeholder to identify opportunities and risks, and develop"

A Genomics Tracker focused on EU-5 (France, Germany, Italy, Spain, United Kingdom) provides updated insight into evaluation, adoption, and use of genomics technologies across solid tumor oncology markets. Data reflect responses from over 100 medical oncologists and offer a cross-market view of current priorities, barriers, and areas of momentum. The Tracker characterizes clinical use across the patient treatment journey including genomic profiling, MRD/recurrence monitoring, and treatment response monitoring, and tracks changes over time. Survey respondents reported use of genomic testing in routine clinical practice within the past three months and assessed familiarity with various vendors. Respondents were eligible if actively practicing medical or hematologist-oncologists who had seen at least 25 patients in the prior three months; nonusers of genomics were not excluded.

Read at Silicon Canals